- Home
- OPRX vs HURA Comparison
OPRX vs HURA Comparison
Compare OPRX & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRX | HURA |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.0M | 160.5M |
| IPO Year | 2008 | 2010 |
Fundamental Metrics
Financial Performance| Metric | OPRX | HURA |
|---|---|---|
| Price | $8.74 | $1.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $12.60 | $8.04 |
| AVG Volume (30 Days) | 168.6K | ★ 208.6K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $4.54 | $0.41 |
| 52 Week High | $22.25 | $3.43 |
Technical Indicators
Market Signals| Indicator | OPRX | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 38.21 |
| Support Level | $6.92 | $1.27 |
| Resistance Level | $9.13 | $1.83 |
| Average True Range (ATR) | 0.41 | 0.11 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.99 | 16.76 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.